As of May 24, 2025, Charles River Laboratories International Inc (CRL) reports a Current Ratio of 1.41.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Charles River Laboratories International Inc's Current Ratio
Over recent years, Charles River Laboratories International Inc's Current Ratio has shown a moderate pattern. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2024-12-28 | 1.41 |
| 2023-12-30 | 1.52 |
| 2022-12-31 | 1.32 |
| 2021-12-25 | 1.23 |
| 2020-12-26 | 1.43 |
This slight downward trend highlights how Charles River Laboratories International Inc manages its short-term assets and liabilities over time.
Comparing Charles River Laboratories International Inc's Current Ratio to Peers
To better understand Charles River Laboratories International Inc's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Charles River Laboratories International Inc (CRL) | 1.41 |
| Replicel Life Sciences Inc (RP.V) | 36.09 |
| Abcellera Biologics Inc (ABCL) | 9.81 |
| Pharma-Bio Serv Inc (PBSV) | 8.32 |
| Personalis Inc (PSNL) | 6.52 |
| Bio Rad Laboratories Inc (BIO) | 6.48 |
Compared to its competitors, Charles River Laboratories International Inc's Current Ratio is about average compared to peers, reflecting balanced short-term asset management.